Baird dental technology report: A modest upside evident in Dentsply, Henry Schein
May 5, 2014
May 5, 2014
The latest dental technology report from Baird Equity Research is out, with Nobel Biocare reporting relatively stable first quarter results. Sales grew in North and South America by 2/5% cc, with positive implant and hardware sales.
The 2014 dental technology outlook and top 10 themes, from Baird
Dentsply and Henry Schein both show modest or potential upsides with evidence of the worldwide dental implant market trends improving.
Align Technology announced a $70 million accelerated stock repurchase plan last week. They expect to fully execute the plan over the next three months.
Overall, Baird “continues to favor” Dentsply and Henry Schein, and they’re “staying patient” on Align.
See the report “Medical Technology: A Few Dental Data Points for Today” in its entirety.
Lauren Burns is the editor of Proofs magazine and the email newsletters RDH Graduate and Proofs. She is currently based out of New York City. Follow her on Twitter: @ellekeid.
ID 332158709 © Dmitriiavramchik | Dreamstime.com
